Merck Patent Gmbh

Ablynx N.v.

Dr. Karl Thomae Gmbh

Merck Patent Gesellschaft

Dr. Karl Tomae Gmbh

Roland Kellner

Hans Guehring

Bjoern Hock

Ralf Guenther

Sven Lindemann

Marie-Ange Buyse

Guy Hermans

Gunther Jung

Cortina Kaletta

Friedrich Gotz

Klaus Duecker

Karl-Dieter Entian

Thomas Kupke

Ralf Rosenstein

Germar Engelke

Johannes Augustin

Norbert Schnell

Cora Klein

Bernd Wieland

Frank Zenke

Soren Steffensen

Gerald Beste

Christoph Hubertus Ladel

Ansgar Wegener

Lars Toleikis

Joerg Bomke

Susanne Klumpp

The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.

ADAMTS binding immunoglobulins

The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as 'polypeptides of the invention', and 'immunoglobulin(s) of the invention', respectively). The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides (also referred to herein as &#x201c;nucleic acid(s) of the invention&#x201d;; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein.

Polypeptides binding ADAMTS5, MMP13 and aggrecan

The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein.

The invention relates to a method for screening compounds, which inhibit MetAP2 activity, by providing a cellular system or a sample thereof being capable of expressing MetAP2 and/or EEF1A, incubating at least a portion of the system with compounds to be screened, and detecting MetAP2 inhibition by determining EEF1A with N-terminal methionine residue (MetEEF1A). Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by MetAP2 activity, by administering an effective amount of at least a single compound to a mammal in need of such treatment and determining MetEEF1A in a biological sample withdrawn from the mammal. The invention also relates to the use of EEF1A as biomarker.

Use of EEF1A as biomarker and a method of screening MetAP2 inhibitors

180 KDa protein histidine phosphatase interacting protein (PHPIP-180) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-180 polypeptides and polynucleotides in diagnostic assays.

180 kD protein that interacts with protein histidine phosphatase 1

The present invention relates to the use of compounds and to methods for the qualitative and/or quantitative determination of the activity of phosphoamidases or protein phosphoamidases specific for hydrolyzing phosphoamide (P&#x2014;N) bonds N-phosphorylated basic amino acids like phospholysine, phosphoarginine and phosphohistidine.

Phosphoamidase assay

PHPIP-240 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-240 polypeptides and polynucleotides in diagnostic assays.

Histidine phosphatase interacting protein with 240kD

PHPIP-120 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed, also disclosed are methods for utilizing PHPIP-120 polypeptides and polynucleotides in diagnostic assays.

Histidine phosphatase interacting protein with 120kD

The invention relates to a novel enzyme, histidine protein phosphatase, which is derived from mammalian sources, and its homologue variants. The invention further relates to DNA sequences encoding said proteins, to a process for preparing the latter, and to antibodies directed against them. The novel phosphatase can be used for diagnosis of pathological states of cell regulation and cell growth and as pharmaceutical drug which can be administered in conjunction with pathological disorders related to malfunctions of said enzyme.

Histidine protein-phosphatase

A bacterial host is described which is transformed by a plasmid coding for a polypeptide precursor wherein the host comprises a multi-enzyme complex capable of reacting with the expressed polypeptide precursor to produce a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge. A process for producing a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge, such as gallidermin, is also described. A plasmid capable of transforming a bacterial host is additionally described. Also disclosed are recombinant DNA molecules which specify Epi B, Epi C, Epi D, Epi P and Epi Q, enzymes which are involved in the biosynthesis of lantibiotic epidermin.

Biosynthetic process for the preparation of chemical compounds

A bacterial host is described which is transformed by a plasmid coding for a polypeptide precursor wherein the host comprises a multi-enzyme complex capable of reacting with the expressed polypeptide precursor to produce a polypeptide comprising at least one dehydroamino acid and/or at least one lanthionine bridge. A process for producing a polypeptide comprising at least one dehydroamino acid and/or at least one lanthionine bridge, such as gallidermin, is also described. A plasmid capable of transforming a bacterial host is additionally described. Also disclosed are recombinant DNA molecules which specify Epi B, Epi C, Epi D, Epi P and Epi Q, enzymes which are involved in the biosynthesis of lantibiotic epidermin.

Growing community of inventors

Heppenheim, Germany

Roland Kellner